Addex to Present at the Biotech and Money Inv€$tival Showcase and Participate in the Jefferies London Healthcare Conference

Addex Selective mGlu2 PAM ADX71149 Included in Review Highlighting Promising Investigative Drugs for Epilepsy

Addex to Present at the Sachs 18th Annual Biotech in Europe Forum

Addex Reports 2018 Half-Year Financial Results and Provides Corporate Update

Addex to Present at the Investora Zurich Conference on 27 September

ADDEX THERAPEUTICS RECOGNISED IN FINAL SHORTLIST FOR DEAL OF THE YEAR AT LIFESTARS AWARDS LIFE SCIENCE AWARDS FOR PARTNERSHIP WITH INDIVIOR

Addex ADX10061 Receives £1.2 million Funding for Manufacture and Investigator Led Clinical Studies as part of the Tools for Human Drug and Brain Research (THuNDR2) Initiative from the Wellcome Trust

Addex’s Selective mGlu2 PAM ADX71149 Shows Promise in Treating Severe Panic Disorders and PTSD

Van Leeuwenhoeck Issues Equity Research Note Highlighting Addex Investment Opportunity

Addex Shareholders Approve All Resolutions at Annual General Meeting